Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function

Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site

(2016) Xiaoxin Wu et al.   Anti-Cancer Agents in Medicinal Chemistry

VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification

(2015) S. Pundir et al.   CANCER RESEARCH

Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments

(2015) Ya-Ting Ji et al.   CURRENT MEDICINAL CHEMISTRY

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

(2015) Shundong Cang et al.   Journal of Hematology & Oncology

Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy

(2015) Anna Barbuti et al.   Cancers

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

(2014) S. Peirs et al.   BLOOD

Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells

(2014) S Colak et al.   CELL DEATH AND DIFFERENTIATION

Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones

(2014) Danielle Jandial et al.   CURRENT CANCER DRUG TARGETS

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

Ansamitocin P3 Depolymerizes Microtubules and Induces Apoptosis by Binding to Tubulin at the Vinblastine Site

(2013) Jubina B. Venghateri et al.   PLoS One

CIL-102 binds to tubulin at colchicine binding site and triggers apoptosis in MCF-7 cells by inducing monopolar and multinucleated cells

(2012) K.K. Gireesh et al.   BIOCHEMICAL PHARMACOLOGY

Anti-breast cancer activity of heteroaryl chalcone derivatives

(2012) V.Raja. Solomon et al.   BIOMEDICINE & PHARMACOTHERAPY

Prospective Clinical Trial to Compare Vincristine and Vinblastine in a COP-Based Protocol for Lymphoma in Cats

(2012) E.L. Krick et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

(2012) Yan Lu et al.   PHARMACEUTICAL RESEARCH

An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics

(2012) Ankit Rai et al.   PLoS One

Mammalian multidrug-resistance proteins (MRPs)

(2011) Andrew J. Slot et al.   Essays in Biochemistry

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

TPPP/p25 Promotes Tubulin Acetylation by Inhibiting Histone Deacetylase 6

(2010) Natália Tőkési et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones

(2009) Sylvie Ducki et al.   BIOORGANIC & MEDICINAL CHEMISTRY

A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivoglioblastoma models

(2009) Ahcene Boumendjel et al.   BMC CANCER

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents

(2009) C Stengel et al.   BRITISH JOURNAL OF CANCER

S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton

(2009) Chao Zhang et al.   PLoS One

Microtubule assembly dynamics: An attractive target for anticancer drugs

(2008) Parminder Singh et al.   IUBMB LIFE

Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?

(2008) Pascal Sève et al.   LANCET ONCOLOGY